A new mesothelioma indication for Bristol Myers Squibb Company’s Opdivo and Yervoy combination capped a week otherwise notable for two complete response letters – for Mesoblast’s remestemcel-L and Aquestive’s Libervant (buccal diazepam) – and a host of pediatric approvals from the US Food and Drug Administration.
The FDA’s biggest approval decisions last week came down against approval, with complete response letters announced for Mesoblast Limited’s...





